Article Listing - Protalix and Pfizer expand Elelyso agreement

USTR SAYS "WAIT AND SEE" ON INDIAN PATENTS

16 March 1992

The USA is to take no retaliatory action for the present against India under the Special 301 provisions of the...

EXPANDED PHASE II STUDY FOR TLC G-65

16 March 1992

The Liposome Co reports that it has initiated an expanded Phase II trial with its proprietary TLC G-65 for the...

FOCUS ON JANSSEN'S RISPERDOL

16 March 1992

The forthcoming launch of Janssen's new potent combined 5-HT2/ dopamine D2 receptor antagonist antipsychotic Risperdol (risperidone) could represent a major...

ITALY'S RECORDATI SEEKS US CR PARTNER

16 March 1992

Speaking at a Mabon Securities' meeting in New York, the Italian drugmaker Recordati made it be known that it was...

UK CHILDHOOD VACCINATION FEARS

16 March 1992

Only 60%-70% of five-year-olds in inner London have been fully immunized against the major childhood diseases, says a new study.

Nationwide,...

EURO MARKETS FOR PATIENT MONITORING

16 March 1992

The European market for patient monitoring consumables will continue to grow until the mid-1990s, from a value of just under...

FRENCH HEALTH SECTOR REFORMS

16 March 1992

Strong, domestically-owned companies with a high level of domestic investment, such as Rhone-Poulenc Rorer and Sanofi, will have less to...

APPOINTMENTS AT HOUSTON BIOTECH

16 March 1992

- At Houston Biotechnology, Douglas Peabody has been named as chairman of the board of directors, and Russell Denson...

REPLIGEN APPOINTMENT

16 March 1992

- John Kenward takes the newly-created position of chief operating officer at Repligen.

ANALYST EMPLOYMENT MOVES

16 March 1992

- UK pharmaceuticals analyst Percy Lomax has joined Fleming, moving from Shep-pards. And Mark Tracey has moved from Paribas to...